News
Massachusetts health insurers are effectively telling the drug companies that they may seek a rapidly growing customer base ...
2d
Discover Magazine on MSNOzempic and Other GLP-1 Side Effects May Outweigh the BenefitsG lucagon-like peptide-1 receptor agonists (GLP-1RA) drugs, such as Ozempic and Wegovy, are often referred to as "miracle ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...
Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...
The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...
GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...
1d
CivicScience on MSNGLP-1 Trends by CivicScience: Access and Shortages, Desire for Customized Products, and Self-Care PreferencesThis is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...
20h
Packaging Gateway on MSNNordic Cold Chain launches cold chain packaging for GLP-1 drugsTemperature-controlled packaging solutions provider Nordic Cold Chain Solutions has introduced what it claims to be the first cold chain packaging solution tailored for transporting glucagon-like ...
GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.
Here’s a roundup of numbers from the last week of HR news — including the percentage of managers who use AI to help determine ...
4d
Everyday Health on MSN9 Signs Your Compounded GLP-1 Supplier Is ShadySome online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results